- Home
- INV vs INBX Comparison
INV vs INBX Comparison
Compare INV & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INV
- INBX
- Stock Information
- Founded
- INV 2015
- INBX 2010
- Country
- INV United States
- INBX United States
- Employees
- INV N/A
- INBX N/A
- Industry
- INV
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- INV
- INBX Health Care
- Exchange
- INV NYSE
- INBX Nasdaq
- Market Cap
- INV 173.3M
- INBX 178.5M
- IPO Year
- INV N/A
- INBX 2020
- Fundamental
- Price
- INV $4.86
- INBX $12.33
- Analyst Decision
- INV Strong Buy
- INBX Hold
- Analyst Count
- INV 2
- INBX 1
- Target Price
- INV $14.00
- INBX N/A
- AVG Volume (30 Days)
- INV 58.5K
- INBX 95.1K
- Earning Date
- INV 05-15-2025
- INBX 05-14-2025
- Dividend Yield
- INV N/A
- INBX 6.93%
- EPS Growth
- INV N/A
- INBX N/A
- EPS
- INV N/A
- INBX 111.58
- Revenue
- INV $1,220,000.00
- INBX $200,000.00
- Revenue This Year
- INV $1,336.39
- INBX N/A
- Revenue Next Year
- INV $204.86
- INBX N/A
- P/E Ratio
- INV N/A
- INBX $0.11
- Revenue Growth
- INV 18.27
- INBX N/A
- 52 Week Low
- INV $3.00
- INBX $10.80
- 52 Week High
- INV $18.75
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- INV N/A
- INBX 53.00
- Support Level
- INV N/A
- INBX $10.84
- Resistance Level
- INV N/A
- INBX $11.98
- Average True Range (ATR)
- INV 0.00
- INBX 0.84
- MACD
- INV 0.00
- INBX 0.07
- Stochastic Oscillator
- INV 0.00
- INBX 75.25
About INV INNVENTURE INC
Innventure Inc creates, funds, operates, and rapidly scales companies in strategic collaboration with MNCs. It provides company creation, corporate strategy, technology optimization, operations, commercialization, and funding. Innventure analyzes the market, including proprietary data provided by MNCs, to identify where their well-protected, breakthrough technologies address market needs and have the potential to create $1B+ in new enterprise value.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.